Allterum Therapeutics is building an oncology franchise targeting the IL-7 axis starting with a monoclonal antibody against CD127 (also known as IL-7Rα).
Developing treatments for
WHO WE ARE
Allterum Therapeutics, Inc., is a biopharmaceutical company targeting the IL-7 pathway for the treatment of IL-7R expressing cancers. Allterum was founded in 2018 by Fannin Innovation Studio in Houston, TX.
Why Allterum Therapeutics
Our Partnerships & Collaborators
``I am excited to work with Allterum to develop a much-needed option for the treatment of children with T-cell ALL.``
Eric Schafer, M.D., M.H.S.Assist. Professor, Pediatrics-Oncology | Texas Children's Hospital & Baylor College of Medicine
”After years of searching for a way to help those kids who have no effective treatment for their leukemia, I’m thrilled to see Allterum take our antibody into the clinic.”
Scott Durum, Ph.D.Inventor | Cytokine and Immunity Section | National Cancer Institute
STAY UP TO DATE
Advancing an innovative solution for a critical and unmet medical need